What we achieved in 2025, together
Date
Research news
Date
Results from a one-year project, funded through the Parkinson’s Virtual Biotech, suggest that NLX-112 has potential as a future treatment for reducing dyskinesia and improving movement symptoms of Parkinson’s.
Date
Herantis Pharma has published initial results from a phase 1/2 study of an experimental protective protein called CDNF which may hold potential to slow, stop or reverse Parkinson's.
Date
GDNF clinical trial results in 2019 revealed signs that GDNF may make it possible to repair the cells damaged in people with Parkinson’s. We take a look at where we are 1 year later.
Date
A promising molecule, called BT13, has offered hope for a new treatment that could stop or slow Parkinson’s, something no treatment can currently do.
Date
New research suggests that a bacteria which boosts digestive health can slow – and even reverse – the build-up of a protein associated with Parkinson’s.
Date
In our survey of more than 2,000 people, more than a quarter (26%) reported they were misdiagnosed with a different condition before receiving the correct Parkinson’s diagnosis.
Date
Researchers, funded by Parkinson's UK, have produced positive results in mice for a gene therapy treatment that directly targets the production of the alpha-synuclein protein.
Date
Alongside Alzheimer’s Research UK, we’re funding new research that will investigate whether boosting the brain’s self-cleaning system could be the key to new treatments.
Date
Former professional footballers are more likely to die with a neurodegenerative condition such as dementia or Parkinson's than the general population, according to new research.
Date
Earlier this year, we surveyed 1,600 people with Parkinson's and 29 health professionals about using cannabis-derived products. Here are the results.